Nerve Growth FactorPhase III

1019 patients (504 NGF, 515 placebo)

Primary: Change in NIS-LL (17-24,28,29, 34-37 in NIS)

Secondary: QST, Neuropathy Symptom and Change Questionnaire, NCV, filament

Unsuccessful

Previous slide

Next slide

Back to first slide

View graphic version